Article info
PDFRheumatoid arthritis
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab
- Correspondence to Professor Daniel Aletaha, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090 Vienna, Austria; daniel.aletaha{at}meduniwien.ac.at
Citation
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab
Publication history
- Received July 9, 2019
- Revised March 31, 2020
- Accepted April 6, 2020
- First published May 5, 2020.
Online issue publication
June 14, 2020
Article Versions
- Previous version (5 May 2020).
- Previous version (1 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.